Skip to content
2000
Volume 31, Issue 35
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

The application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/- Cas9 in treating CRC. Further in-depth and systematic research is required to fully realize the potential of CRISPR/Cas9 in CRC treatment and integrate it into clinical practice.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867331666230915103707
2024-10-01
2025-01-27
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867331666230915103707
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test